FDA OKs Teva's Austedo for HD chorea; shares ahead 2% premarket

|About: Teva Pharmaceutical In... (TEVA)|By:, SA News Editor

Teva Pharmaceutical Industries (NYSE:TEVA) is up 2% premarket on modestly higher volume in response to its announcement that the FDA has approved AUSTEDO (deutetrabenazine) tablets for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease (HD), an Orphan Drug indication.

HD is a neurodegenerative disease that affects more than 35K Americans each year.